Ahlehoff Ole, Hansen Peter Riis
Kardiologisk Afdeling P, Gentofte Hospital, DK-2900 Hellerup, Denmark.
Ugeskr Laeger. 2009 Dec 7;171(50):3705-7.
Ranolazine sustained-release tablets were recently approved in the EU for chronic stable angina as add-on therapy when symptoms are not controlled with first-line agents. The mechanism of action is thought to involve inhibition of late sodium influx in the heart, which can reduce abnormalities of contractility and repolarisation associated with ischaemia. Ranolazine increases the exercise capacity, reduces angina, and diminishes the use of nitroglycerine. The drug has an excellent safety profile and may be a valuable addition to the treatment of chronic stable angina.
雷诺嗪缓释片最近在欧盟被批准用于慢性稳定型心绞痛，作为一线药物无法控制症状时的附加治疗。其作用机制被认为涉及抑制心脏晚期钠内流，这可以减少与缺血相关的收缩性和复极化异常。雷诺嗪可提高运动能力、减轻心绞痛并减少硝酸甘油的使用。该药物具有出色的安全性，可能是慢性稳定型心绞痛治疗的一项有价值的补充。
